<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778919</url>
  </required_header>
  <id_info>
    <org_study_id>KLH1204</org_study_id>
    <nct_id>NCT02778919</nct_id>
  </id_info>
  <brief_title>Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kissei Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kissei Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, and dose-response relationship
      of KLH-2109 compared to placebo in Japanese patients with endometriosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 9, 2016</start_date>
  <completion_date type="Actual">March 23, 2018</completion_date>
  <primary_completion_date type="Actual">March 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Change of average Numerical Rating Scale (NRS) score of pelvic pain</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidences of adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>KLH-2109, lowest dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KLH-2109, low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KLH-2109, medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>KLH-2109, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>First 12 week period; Placebo, Second 12 week period; randomize to one of the KLH-2109 dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leuprorelin acetate</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active reference</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KLH-2109</intervention_name>
    <arm_group_label>KLH-2109, high dose</arm_group_label>
    <arm_group_label>KLH-2109, low dose</arm_group_label>
    <arm_group_label>KLH-2109, lowest dose</arm_group_label>
    <arm_group_label>KLH-2109, medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>KLH-2109, low dose</arm_group_label>
    <arm_group_label>KLH-2109, lowest dose</arm_group_label>
    <arm_group_label>KLH-2109, medium dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprorelin acetate</intervention_name>
    <arm_group_label>Leuprorelin acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients with endometriosis

        Exclusion Criteria:

          -  Patients with clinically significant hepatic, renal, or cardiovascular dysfunction
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2016</study_first_posted>
  <last_update_submitted>June 3, 2019</last_update_submitted>
  <last_update_submitted_qc>June 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometriosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

